anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recommended doses of maraviroc for adult patients with impaired renal function (CrCl less than or equal to 80 mL per minute) are based on the results of a pharmacokinetic trial conducted in healthy adult subjects with various degrees of renal impairment. Maraviroc has not been studied in pediatric patients with renal impairment. There are no data to recommend specific doses of maraviroc in pediatric patients with mild to moderate renal impairment [ see Use in Specific Populations ( 8.4) ]. Maraviroc is contraindicated in pediatric patients with severe renal impairment or ESRD on regular hemodialysis who are receiving potent CYP3A inhibitors [ see Contraindications ( 4) ]. 

  
  


The pharmacokinetics of maraviroc in adult subjects with mild and moderate renal impairment was similar to that in subjects with normal renal function [ see Clinical Pharmacology ( 12.3) ]. A limited number of adult subjects with mild and moderate renal impairment in the Phase 3 clinical trials (n = 131 and n = 12, respectively) received the same dose of maraviroc as that administered to subjects with normal renal function. In these subjects, there was no apparent difference in the adverse event profile for maraviroc compared with subjects with normal renal function.   
  
If adult patients with severe renal impairment or ESRD not receiving a concomitant potent CYP3A inhibitor or inducer experience any symptoms of postural hypotension while taking maraviroc 300 mg twice daily, the dose should be reduced to 150 mg twice daily. No trials have been performed in subjects with severe renal impairment or ESRD co-treated with potent CYP3A inhibitors or inducers. Hence, no dose of maraviroc can be recommended, and maraviroc is contraindicated for these patients [ see Dosage and Administration ( 2.3), Contraindications ( 4), Warnings and Precautions ( 5.3), Clinical Pharmacology ( 12.3) ].
Heart disease is the leading cause of death for men and women in the United States. For patients with documented coronary artery disease (CAD), anti-platelet agents, beta-blockers and statins have all been shown to improve survival and reduce the frequency of myocardial infarction. Yet, previous research by the Duke CERTs has shown that in a population of over 28,000 patients with documented CAD, only 21% reported consistent use of triple therapy with aspirin, beta-blockers and lipid lowering therapy. These results stimulated the Duke CERTs to devise an intervention to improve adherence to these life-saving medications.

Comparisons: Patients admitted to Duke University Hospital or Southeastern Regional Medical Center (SRMC) with CAD or CAD plus heart failure who agree to participate, will be randomized to an intervention or control arm. The control group will receive usual care, which consists of routine discharge counseling performed by the patient-care nurse and a letter/discharge summary from the Duke physician to the community physician. In addition to usual care, the intervention group will receive focused medication counseling in the hospital by the clinical pharmacist-investigator, who will identify and address potential barriers to medication adherence and will reinforce the importance of taking evidence-based medications long term. Discharge medications will be shared with the community pharmacist. The community pharmacist will monitor for problems with adherence and communicate issues back to the patient and the patient's care team.
Enhanced Recovery After Surgery (ERAS) is a series of measures designed to promote early recovery after surgery. Application of this approach has led to significantly decreased morbi-mortality and reduced length of hospital stay. The aim of our study was to determine whether non-completion of the ERAS protocol following robotic-assisted mini-invasive lobectomy could be the cause of prolonged hospital stay (exceeding 6 days). We conducted a longitudinal retrospective analysis of 34 patients (17 men and 17 women) having undergone robotic-assisted lobectomy for early-stage primary lung carcinoma from January 1, 2022 to December 31, 2022. The study population was divided into two groups based on length of hospital stay: group 1 with length of stay not exceeding 6 days and group 2 with a stay of 7 days or more. Comparative analysis showed no significant difference in ERAS completion score between the two groups, whatever the preoperative (P=0.15), perioperative (P=0.73) or postoperative (P=0.97) time. That said, prolonged air leak (P=0.01) was the main difference among the analyzed variables, followed by Charlson score (P=0.01), grade of complications (P=0.03) and smoking status (P=0.01). Incorporation of complementary measures in our ERAS protocol strategy would in all probability optimize air leak management and further reduce length of hospital stay.
The present invention provides a inhalation-type pharmaceutical composition for treating diabetes comprising a first gas and an atomized drug and a preparation method thereof. The first gas contains hydrogen. In the inhalation-type pharmaceutical composition, the volume concentration of hydrogen is 2 to 96%. An atomized drug is selected from a group consisting of metformin hydrochloride, glibenclamide, glucobay, rosiglitazone maleate, insulin, and a random combination thereof. The inhalation-type pharmaceutical composition eliminates harmful radical in a patient′s body through an usage of hydrogen, and may increase absorption by using the atomized pharmaceutical composition. At the same time, a side effect may be indirectly decreased due to using a small amount of evaporated pharmaceutical fluid.
Deep repetitive transcranial magnetic stimulation (dTMS) is a technique that stimulates areas of the brain using magnetic pulses and is an approved treatment for several mental health and substance use disorders. The treatment uses head coils to deliver the magnetic pulses. A dTMS coil called the H4 coil stimulates the lateral prefrontal cortex and insula, and has been approved for the treatment of tobacco use disorder. No studies have been conducted on the H4 coil for treat cannabis use disorder. The purpose of this pilot study is to determine feasibility and tolerability of a dTMS H4 protocol. The goal is to lay the foundation for randomized controlled trials of dTMS as a treatment for adults with moderate-to-severe cannabis use disorder.
A randomized open label clinical trial is planned in 4 worksites. The total study duration is 18 months. Four workplace sites will be divided into two active intervention and two control sites. Intensive awareness generation activities for overweight and obese employees and a general awareness health, nutrition and physical education programme for the rest of the employees. The study subjects will be part of awareness sessions which will be conducted in the 6 month intervention period. Besides group sessions individual diet charts will also be worked out by a trained nutritionist. Physical activity advice will be provided to them keeping their specific requirements in mind. Pedometers will be provided to them and they will be encouraged to walk for 15 minutes in pre-lunch period. Leg movements at the desk will also be encouraged.
BACKGROUND: Existing PK models of propofol include sparse data from very obese patients. The aim of this study was to develop a PK model based on standardised surgical conditions and spanning from normal-weight up to, and including, a high number of very obese patients.
METHODS: Adult patients scheduled for laparoscopic cholecystectomy or bariatric surgery were studied. Anaesthesia was induced with propofol 2 mg/kg adjusted body weight over 2 min followed by 6 mg/kg/h adjusted body weight over 30 min. For the remainder of the operation anaesthesia was maintained with sevoflurane. Remifentanil was dosed according to clinical need. Eight arterial samples were drawn in a randomised block sampling regimen over a span of 24 h. Time-concentration data were analysed by population PK modelling using non-linear mixed-effects modelling.
RESULTS: Four hundred and seventy four serum propofol concentrations were collected from 69 patients aged 19-60 years with a BMI 21.6-67.3 kg/m2. Twenty one patients had a BMI above 50 kg/m2. A 3-compartment PK model was produced wherein three different body weight descriptors and sex were included as covariates in the final model. Total body weight was found to be a covariate for clearance and Q3; lean body weight for V1, V2 and Q2; predicted normal weight for V3 and sex for V1. The fixed allometric exponent of 0.75 applied to all clearance parameters improved the performance of the model. Accuracy and precision were 1.4% and 21.7% respectively in post-hoc performance evaluation.
CONCLUSION: We have developed a new PK model of propofol that is suitable for all adult weight classes. Specifically, it is based on data from an unprecedented number of individuals with very high BMI.
The present disclosure provides a method for preparing a ferment of Chinese herbal medicine including the following steps. A fermenting substrate is provided, wherein the fermenting substrate includes a Chinese herbal material and water, and the Chinese herbal material is composed of Astragalus membranaceus, Atractylodes macrocephala, Ampelopsis japonica, Polygonatum sibiricum, Ligusticum striatum, Prunus Amygdalus and Saposhnikovia divaricata. A fermenting fungi solution is provided, wherein the fermenting fungi solution includes a yeast. A fermentation step is performed, wherein the fermenting material and the fermenting fungi solution are mixed so as to obtain a mixture, and the mixture is cultured so as to obtain a fermented product. A solid component of the fermented product is removed so as to obtain the ferment of Chinese herbal medicine. Therefore, the active ingredients of the Chinese herbal material can be effectively extracted and the activities thereof can be retained. In addition, the present disclosure also provides a skin complexion improved composition including the ferment of Chinese herbal medicine.
The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies. Metabolic Meals will be delivered to KETO subjects' homes via courier, consisting of 3 meals a day plus snacks, targeting 70% fat, 20% protein, 10% carbohydrates.
Action Observation + Motor imagery Group. Both action observation and motor imagery interventions will be applied for 5 minutes each.
PROBLEM TO BE SOLVED: To obtain a new and safe lipase activity-stimulating agent, a moisturizing agent, beautifully whitening agent, contact dermatitis-inhibiting agent, skin external use agent, bath agent, drink or food by compounding a specific plant extract as an active ingredient. SOLUTION: This skin. preparation for external use contains the extract of one or more plants selected from Agave americana L., Agave sisalana Perr.; A. rigida Mill., etc. The extract has a lipase activity-stimulating action, a moisture-retaining action, a melamine production-inhibiting action, and a contact dermatitis-inhibiting action. The extract is preferably compounded in an amount of 0.1-60 wt.%. The medicine is effective for inhibiting the fat secretion of skin and scalp, for treating the diseases of fatty skin (e.g. acnes, dander), hand roughness, itching, dry skin, etc.
The present invention provides, among other things, methods of treating a muscular dystrophy including administering to a subject suffering from or susceptible to a muscular dystrophy an angiotensin (1-7) peptide. The present invention is, in part, based on the unexpected discovery that administration of an angiotensin (1-7) peptide in a muscular dystrophy animal model reduces fibrosis, restores locomotor activity and restores sympathovagal balance, which are characteristic symptoms in patients suffering from muscular dystrophy. Thus, the present invention provides a new and more effective therapy for muscular dystrophy. In some embodiments, an angiotensin (1-7) peptide includes the naturally occurring angiotensin (1-7) amino acid sequence of Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7 (SEQID NO:1). In some embodiments, the angiotensin (1-7) peptide is a functional equivalent of SEQ ID NO:1. In some embodiments, the linear peptide has an amino acid sequence of Asp1-Arg2-Val3-Ser4-Ile5-H′is6-Cys7 (SEQ ID NO:2). In some embodiments, the cyclic peptide is a 4,7-cyclized angiotensin (1-7).
FIELD: medicine, pediatry, virology, vaccines. SUBSTANCE: vaccine strain A/47/New Caledonia /99/156 (H1N1) is a reassortant obtained by crossing epidemic virus A/New Caledonia/20/99 (H1N1) with virus A/Leningrad/134/47/57 (H2N2) as attenuation donor that is harmless for children and its properties ensure a possibility to obtain guaranteed reassortant vaccine strains from newly appearing epidemic viruses. The strain A/47/New Caledonia/99/156 (H1N1) multiplies actively in developing chicken embryos at optimal temperature 33-34 C and shows temperature-sensitivity and cold-adaptation. Reassortant inherited from epidemic virus two genes encoding surface proteins (hemagglutinin and neuraminidase) and six genes encoding nonglycosylated proteins from attenuation donor. The strain A/47/New Caledonia/99/156 (H1N1) is areactogenic for children in age 3-14 years in intranasal route of its administration. Thus, vaccine strain A/47/New Caledonia/99/156 (H1N1) corresponds to biological properties and indices of reactivity to requirements imposing by Pharmacopoeia article 42-3353-97 for live influenza vaccine for intranasal administration in children of age 3-14 years. EFFECT: improved method of preparing, valuable properties. 1 tbl, 1 ex
Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
OBJECTIVE: Carotid-cavernous fistulas (CCFs) are rare arteriovenous communications allowing blood to flow from the carotid artery into the cavernous sinus. Although currently coil and/or liquid embolization remain the preferred treatment methods for CCFs, flow diverters (FD) stents represent a viable alternative to traditional embolization techniques. This study explores both the technical aspects and rationale behind using FD stents as a stand-alone treatment approach for CCFs.
METHODS: The study includes records of 7 patients with CCFs treated at two comprehensive stroke centers from 2019 to 2023. Patients treated with FD stenting in conjunction with coil and/or liquid embolization were excluded from the study.
RESULTS: Five patients were diagnosed with direct CCFs and 2 patients with indirect CCFs. Six patients were treated with the Surpass Evolve FD stent and 1 patient with the Pipeline FD stent. DSA follow-up was performed for an average duration of 14.4 months following FD placement. Complete fistula obliteration with no residual shunting was observed in all patients. Furthermore, all patients experienced a complete resolution of symptoms following treatment.
CONCLUSIONS: The authors' experiences suggest the efficacy and safety of FD stenting as a stand-alone treatment option for CCFs. Compared to embolization, FD stents can better preserve the parent vessel and promote healing with less associated mass effect. Despite being a retrospective self-assessment with a relatively small sample size, to the authors' knowledge, this study represents the largest individual case series of patients with CCF treated with stand-alone FD stenting.
Epilepsy is one of the most well-known neurological disorders globally, leading to individuals experiencing sudden seizures and significantly impacting their quality of life. Hence, there is an urgent necessity for an efficient method to detect and predict seizures in order to mitigate the risks faced by epilepsy patients. In this paper, a new method for seizure detection and prediction is proposed, which is based on multi-class feature fusion and the convolutional neural network-gated recurrent unit-attention mechanism (CNN-GRU-AM) model. Initially, the Electroencephalography (EEG) signal undergoes wavelet decomposition through the Discrete Wavelet Transform (DWT), resulting in six subbands. Subsequently, time-frequency domain and nonlinear features are extracted from each subband. Finally, the CNN-GRU-AM further extracts features and performs classification. The CHB-MIT dataset is used to validate the proposed approach. The results of tenfold cross validation show that our method achieved a sensitivity of 99.24% and 95.47%, specificity of 99.51% and 94.93%, accuracy of 99.35% and 95.16%, and an AUC of 99.34% and 95.15% in seizure detection and prediction tasks, respectively. The results show that the method proposed in this paper can effectively achieve high-precision detection and prediction of seizures, so as to remind patients and doctors to take timely protective measures.
HAT1 topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
FIELD: medicine, pharmacology, sanitary science and dermatology.SUBSTANCE: invention relates to the field of medicine, namely pharmacology, sanitary science and dermatology and is intended for use against a wide range of pathogenic bacteria and fungi. For the use against one or more pathogenic bacteria or fungi, a baby powder containing a base component and an active component is used. The base component is selected from the group consisting of talc, starch, flour, chalk, montmorillonite clay, finely ground eggshell, natural zeolite shivyrtuin-montorillite zeolite and pectin, and Neolactoferrin is used as the active component. "Neolactoferrin" constitutes a complex of 10% goat lactoferrin and 90% biosimilar human lactoferrin. The components are used in the labeled amounts. One or more bacteria or yeast associated with the infection is selected from the group consisting of methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, coagulase-negative staphylococci (CoNS), vancomycin-resistant enterococcus (VRE), carbapenem-resistant Klebsiella pneumonia, Pseudomonas aeruginosa, Acinetobacter baumannii, methicillin-resistant Staphylococcus pseudintermedius (MRSP), Malassezia pachydermatis, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, Campylobacter jejuni, Bacillus spp., Candida albicans, Streptococcus agalactiae, Streptococcus uberis, Esherichia coli, Salmonella choleraesuis, Stenotrophomonas maltophilia, Enterococcus faecalis, Proteus mirabilis, Klebsiella species pluralis., Enterobacter species pluralis.and Citrobacter species pluralis.EFFECT: use of the invention enables to increase efficiency of prevention and treatment of infectious skin pathology, provides convenience in practical use, ensures long-term storage, has no contraindications, and allows its safe use with newborns as a prophylactic agent to reduce the risk of infectious skin pathology.1 cl, 6 dwg, 3 tbl, 2 ex
The invention provides a dissolvable doxycycline powder and a preparation method thereof, and belongs to the technical field of veterinary broad-spectrum antibacterial medicinal preparations. The dissolvable doxycycline powder comprises the following raw materials in percentage by weight: 5-10% of doxycycline, 20-30% of beta-cyclodextrin, 0.2-3% of sodium lauryl sulfate and 57%-74.8% of glucose. The beta-cyclodextrin serves as an inclusion agent, the sodium lauryl sulfate serves as a surfactant, and the glucose serves as an auxiliary material. The dissolvable doxycycline powder is prepared by a saturated water solution method, the preparation method is simple in technological process, and the dosage form of the dissolvable doxycycline powder is powder. The researched and prepared dissolvable doxycycline powder is good in stability and good in palatability, has good stability, and is easy to store. Compared with the traditional mode of administration through fodder, the dissolvable doxycycline powder can be administrated at any time, and is convenient to take, and a new doxycycline pharmacy mode is provided for markets, for example, the dissolvable doxycycline powder can serve as a mixed-drinking agent, a mixed-feeding agent, an additive and the like.
Morphinan derivatives represented by the following general formula (I), tautomers and stereoisomers of the compounds, pharmaceutically acceptable salts thereof, or solvates thereof are used as anxiolytics, antidepressants, and the like. (in the formula, R 1 Represents hydrogen, C 1－10 Cycloalkyl alkyl groups in which the number of carbon atoms in the cycloalkyl moiety is 3 to 6 and the number of carbon atoms in the alkylene moiety is 1 to 5; r 2 Represents a heterocyclic ring containing 1 to 4 hetero atoms selected from N, O and S and at least 1 carbon atom as ring constituent atoms, and at least 1 group of adjacent ring constituent atoms has a double bond and is further substituted by at least 1 oxo group, wherein Y and R are 2 The carbon atom of the ring-constituting atom of (a) is bonded; r 3 、R 4 And R 5 Represents hydrogen, hydroxyl, etc.; r 6a And R 6b Represents hydrogen, etc.; r 7 And R 8 Represents hydrogen, etc.; r 9 And R 10 The same or different, represent hydrogen, etc.; x represents O or CH 2 And Y represents C (═ O)).
BACKGROUND: Sepsis refers to a systemic inflammatory response caused by infection, involving multiple organs. Sepsis-associated encephalopathy (SAE), as one of the most common complications in patients with severe sepsis, refers to the diffuse brain dysfunction caused by sepsis without central nervous system infection. However, there is no clear diagnostic criteria and lack of specific diagnostic markers.
METHODS: The main active ingredients of coptidis rhizoma(CR) were identified from TCMSP and SwissADME databases. SwissTargetPrediction and PharmMapper databases were used to obtain targets of CR. OMIM, DisGeNET and Genecards databases were used to explore targets of SAE. Limma differential analysis was used to identify the differential expressed genes(DEGs) in GSE167610 and GSE198861 datasets. WGCNA was used to identify feature module. GO and KEGG enrichment analysis were performed using Metascape, DAVID and STRING databases. The PPI network was constructed by STRING database and analyzed by Cytoscape software. AutoDock and PyMOL software were used for molecular docking and visualization. Cecal ligation and puncture(CLP) was used to construct a mouse model of SAE, and the core targets were verified in vivo experiments.
RESULTS: 277 common targets were identified by taking the intersection of 4730 targets related to SAE and 509 targets of 9 main active ingredients of CR. 52 common DEGs were mined from GSE167610 and GSE198861 datasets. Among the 25,864 DEGs in GSE198861, LCN2 showed the most significant difference (logFC = 6.9). GO and KEGG enrichment analysis showed that these 52 DEGs were closely related to "inflammatory response" and "innate immunity". A network containing 38 genes was obtained by PPI analysis, among which LCN2 ranked the first in Degree value. Molecular docking results showed that berberine had a well binding affinity with LCN2. Animal experiments results showed that berberine could inhibit the high expression of LCN2,S100A9 and TGM2 induced by CLP in the hippocampus of mice, as well as the high expression of inflammatory factors (TNFα, IL-6 and IL-1β). In addition, berberine might reduce inflammation and neuronal cell death by partially inhibiting NFκB/LCN2 pathway in the hippocampus of CLP models, thereby alleviating SAE.
CONCLUSION: Overall, Berberine may exert anti-inflammatory effects through multi-ingredients, multi-targets and multi-pathways to partially rescue neuronal death and alleviate SAE.